0001801385-24-000007.txt : 20240228
0001801385-24-000007.hdr.sgml : 20240228
20240228213356
ACCESSION NUMBER: 0001801385-24-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240226
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROMANO KATHRYN
CENTRAL INDEX KEY: 0001801385
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38210
FILM NUMBER: 24698480
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
FORMER NAME:
FORMER CONFORMED NAME: Romano Kathryn
DATE OF NAME CHANGE: 20200128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Krystal Biotech, Inc.
CENTRAL INDEX KEY: 0001711279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 821080209
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
BUSINESS PHONE: (412) 586-5830
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
4
1
wk-form4_1709174024.xml
FORM 4
X0508
4
2024-02-26
0
0001711279
Krystal Biotech, Inc.
KRYS
0001801385
ROMANO KATHRYN
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
PITTSBURGH
PA
15203
0
1
0
0
Chief Accounting Officer
1
Common Stock
2024-02-26
4
M
0
5000
52.26
A
17556
D
Common Stock
2024-02-26
4
S
0
5000
135
D
12556
D
Common Stock
2024-02-26
4
M
0
3087
52.26
A
15643
D
Common Stock
2024-02-26
4
S
0
3087
140
D
12556
D
Common Stock
2024-02-26
4
F
0
1533
157
D
11023
D
Common Stock
2024-02-27
4
M
0
1913
52.26
A
12936
D
Stock Option (Right to Buy)
52.26
2024-02-26
2024-02-26
4
M
0
5000
0
D
2030-01-30
Common Stock
5000
5000
D
Stock Option (Right to Buy)
52.26
2024-02-26
2024-02-26
4
M
0
3087
0
D
2030-01-30
Common Stock
3087
1913
D
Stock Option (Right to Buy)
52.26
2024-02-27
2024-02-27
4
M
0
1913
0
D
2030-01-30
Common Stock
1913
0
D
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $135.00 per share.
The transaction was executed in multiple trades at the same sale price.
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 3,087 shares with a limit price of $140.00 per share.
Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2024.
The closing price on February 26, 2024 of the Company's common stock on NASDAQ.
The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and holding 1,913 shares with a prior closing price from $135.00 per share.
50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021.
/s/ Kathryn Romano
2024-02-28